Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.

Kanska J, Aspuria PP, Taylor-Harding B, Spurka L, Funari V, Orsulic S, Karlan BY, Wiedemeyer WR.

Oncotarget. 2017 Apr 18;8(16):26200-26220. doi: 10.18632/oncotarget.15429.

2.

A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets.

Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S.

Cancer Lett. 2016 Nov 28;382(2):203-214. doi: 10.1016/j.canlet.2016.09.001. Epub 2016 Sep 5.

3.

Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.

Kanska J, Zakhour M, Taylor-Harding B, Karlan BY, Wiedemeyer WR.

Gynecol Oncol. 2016 Oct;143(1):152-158. doi: 10.1016/j.ygyno.2016.07.111. Epub 2016 Jul 25. Review.

PMID:
27461360
4.

Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism.

Aspuria PP, Lunt SY, Väremo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, Karlan BY, Orsulic S.

Cancer Metab. 2014 Dec 15;2:21. doi: 10.1186/2049-3002-2-21. eCollection 2014.

5.

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR.

Oncotarget. 2015 Jan 20;6(2):696-714.

6.

VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

Lim JJ, Yang K, Taylor-Harding B, Wiedemeyer WR, Buckanovich RJ.

Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.

7.

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.

Wiedemeyer WR, Beach JA, Karlan BY.

Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014. Review.

8.

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L.

Cancer Discov. 2012 Aug;2(8):736-49. Epub 2012 Jun 29.

9.

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.

Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11501-6. doi: 10.1073/pnas.1001613107. Epub 2010 Jun 7.

10.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Cancer Genome Atlas Research Network.

Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. Erratum in: Nature. 2013 Feb 28;494(7438):506.

11.

Genomic organization of mouse gene zfp162.

Wrehlke C, Wiedemeyer WR, Schmitt-Wrede HP, Mincheva A, Lichter P, Wunderlich F.

DNA Cell Biol. 1999 May;18(5):419-28.

PMID:
10360842

Supplemental Content

Loading ...
Support Center